Mobile

A randomised, double-blind, parallel-group, placebo-controlled, induction trial to assess the clinical efficacy and safety of NNC0142-0000-0002 in subjects with moderately to severely active Crohn’s d...

Update Il y a 4 ans
Reference: U1111-1116-2695

A randomised, double-blind, parallel-group, placebo-controlled, induction trial to assess the clinical efficacy and safety of NNC0142-0000-0002 in subjects with moderately to severely active Crohn’s disease

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The primary objective of the trial is to compare disease activity following a single s.c. dose of NNC142-0002 to placebo in subjects with moderately to severely active CD, measured 4 weeks after administration.

Inclusion criteria

  • Crohn’s Disease

Links